Merck & Co., Inc. (MRK) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 24, 2026
Merck & Co., Inc. (MRK)
A forensic read on Merck & Co., Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
8.1
Distress distance
Clean
Earnings quality
2
Forensic signals
114.2
P / E (ttm)
34.7%
ROE
$365.3B
Market cap
2.87%
Dividend yield
1.3%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Merck & Co., Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 8.1, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+21.7%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +21.7% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply — a large slice of profit sits in operating assets, not cash. An accrual is a claim that still has to be collected or written down, so the gap resolves in a later period whichever way it goes. The build is led by receivables up +15% against revenue +1% and inventory up +9% against +8% in cost of sales. A cash-flow measure on the same base disagrees: reported earnings ran in line with operating cash by 2% of net operating assets, against an accruals ratio of 21.7%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
107% of FCF
FY2025
Shareholder returns.Returned $13.3B to shareholders (buybacks + dividends) in FY2025 — 107% of free cash flow. That is $900M (7%) more than free cash flow covered. New debt covered it: total debt rose $12.2B over FY2025, while cash, short-term investments and long-term marketable securities rose $1.4B. That ratio has been CLIMBING past free cash flow — 96% of free cash flow two years back — not just sitting there. Counting the $820M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 114%.
Key fundamentals
Latest Revenue$65.01B
Revenue Growth YoY+1.3%
Revenue CAGR (2yr)+4.0%
Net Margin28.1%
Free Cash Flow$12.36B
Return on Equity34.7%
Debt / Equity0.94x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Merck & Co., Inc.'s actual 10-K/10-Q/8-K filings?